HIEs Adding Data Analytics Capabilities
California and Mississippi are investing in health information technology projects that incorporate a broad range of longitudinal patient data and promise insight into population health.
Efforts to upgrade the quality of patient data on statewide health information exchanges are taking a leap forward in California and Mississippi.
In The Golden State, a pair of healthcare payers have announced ambitious plans to launch the California Integrated Data Exchange. Blue Shield of California and Anthem Blue Cross have committed $80 million to operate Cal INDEX for three years.
The HIE will feature longitudinal patient information, which will enable healthcare providers and payers to see a broad range of clinical information over time, such as hospitalizations, medications prescribed, lab results, and allergy histories. This type of data is more comprehensive than encounter-based health records and can be used to study and track population health.
In Mississippi, the state Division of Medicaid has cut a deal with a healthcare analytics firm to create a statewide clinical data repository, a master patient index, and longitudinal patient records for more than 750,000 Medicaid beneficiaries.
No More "Islands of Information"
Cal INDEX is being designed like a public utility, Simon Jones, VP of health information technology product strategy at Blue Shield, said this week. As is the case with utility companies, uniformity and interoperability are key goals for Cal INDEX, he says. "It will allow us to plug information into that grid in a more uniform way."
- Readmissions: No Quick Fix to Costly Hospital Challenge
- How Top-Ranked MA Plans Earn Their Stars
- How Hospitals Can Become 'Upstreamists'
- 4 Ways to Lower the Cost to Collect from Self-Pay Patients
- House Calls Key to Pioneer ACO Success
- How Telehealth Pays Off for Providers, Patients
- 4 Tips for Managing Employed Physicians
- Defensive Medicine Still Prevalent Despite Tort Reform
- WellPoint Dominates Nearly Half of Markets, AMA Says
- 'Overtreatment' Debate Circles Back to Lung Cancer Screening